Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.03-0.61%
| Weiss Ratings | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | D | |||
| Rating Factors | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.45 | |||
| Price History | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.09% | |||
| 30-Day Total Return | 7.42% | |||
| 60-Day Total Return | 6.72% | |||
| 90-Day Total Return | 5.81% | |||
| Year to Date Total Return | 2.07% | |||
| 1-Year Total Return | 29.47% | |||
| 2-Year Total Return | -22.15% | |||
| 3-Year Total Return | -55.52% | |||
| 5-Year Total Return | -39.26% | |||
| 52-Week High % Change | -27.11% | |||
| 52-Week Low % Change | 32.61% | |||
| Price | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.75 | |||
| 52-Week Low Price | $3.71 | |||
| 52-Week Low Price (Date) | Mar 20, 2024 | |||
| 52-Week High Price (Date) | Jun 13, 2024 | |||
| Valuation | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 286.91M | |||
| Enterprise Value | -75.37M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.33 | |||
| Earnings Per Share Growth | -1,028.13% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.44 | |||
| Price/Book (Q) | 0.53 | |||
| Enterprise Value/Revenue (TTM) | -0.38 | |||
| Price | $4.92 | |||
| Enterprise Value/EBITDA (TTM) | 2.32 | |||
| Enterprise Value/EBIT | 1.85 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 58.31M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 202 734 3400 | |||
| Address | 2200 Pennsylvania Avenue NW Washington, DC 20037 | |||
| Website | www.vandapharma.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -20.45% | |||
| Profit Margin | -9.50% | |||
| Management Effectiveness | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.90% | |||
| Return on Equity | -- | |||
| Income Statement | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 198.77M | |||
| Total Revenue (TTM) | 198.77M | |||
| Revenue Per Share | $3.41 | |||
| Gross Profit (TTM) | 187.46M | |||
| EBITDA (TTM) | -32.53M | |||
| EBIT (TTM) | -40.66M | |||
| Net Income (TTM) | -18.90M | |||
| Net Income Avl. to Common (TTM) | -18.90M | |||
| Total Revenue Growth (Q YOY) | 17.48% | |||
| Earnings Growth (Q YOY) | -104.67% | |||
| EPS Diluted (TTM) | -0.33 | |||
| EPS Diluted Growth (Q YOY) | -80.00% | |||
| Balance Sheet | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 374.64M | |||
| Cash Per Share (Q) | $6.43 | |||
| Total Current Assets (Q) | 438.89M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 538.55M | |||
| Current Ratio (Q) | 4.390 | |||
| Book Value Per Share (Q) | $9.24 | |||
| Total Assets (Q) | 656.20M | |||
| Total Current Liabilities (Q) | 99.98M | |||
| Total Debt (Q) | 12.36M | |||
| Total Liabilities (Q) | 117.66M | |||
| Total Common Equity (Q) | 538.55M | |||
| Cash Flow | VNDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -17.43M | |||
| Cash from Financing (TTM) | -155.00K | |||
| Net Change in Cash (TTM) | -33.51M | |||
| Levered Free Cash Flow (TTM) | -27.44M | |||
| Cash from Operations (TTM) | -15.76M | |||
